Literature DB >> 29620581

Coexistence of BRAF V600E and TERT Promoter Mutations in Low-grade Serous Carcinoma of Ovary Recurring as Carcinosarcoma in a Lymph Node: Report of a Case.

Mahkam Tavallaee1, David F Steiner, James L Zehnder, Ann K Folkins, Amer K Karam.   

Abstract

Low-grade serous carcinomas only rarely coexist with or progress to high-grade tumors. We present a case of low-grade serous carcinoma with transformation to carcinosarcoma on recurrence in the lymph node. Identical BRAF V600E and telomerase reverse transcriptase promoter mutations were identified in both the original and recurrent tumor. Given that telomerase reverse transcriptase promotor mutations are thought to play a role in progression of other tumor types, the function of telomerase reverse transcriptase mutations in BRAF mutated low-grade serous carcinoma deserves investigation.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 29620581      PMCID: PMC6170737          DOI: 10.1097/PGP.0000000000000507

Source DB:  PubMed          Journal:  Int J Gynecol Pathol        ISSN: 0277-1691            Impact factor:   2.762


  28 in total

1.  Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.

Authors:  Paul T C Wan; Mathew J Garnett; S Mark Roe; Sharlene Lee; Dan Niculescu-Duvaz; Valerie M Good; C Michael Jones; Christopher J Marshall; Caroline J Springer; David Barford; Richard Marais
Journal:  Cell       Date:  2004-03-19       Impact factor: 41.582

2.  Sarcomatoid carcinoma arising within a serous borderline ovarian tumour: a case report and practical approach to differential diagnosis.

Authors:  T D Andrews; P M Dutton; G Beattie; A Al-Nafussi
Journal:  Histopathology       Date:  2007-09-28       Impact factor: 5.087

3.  Ovarian serous tumor with mural nodules of carcinomatous derivation (sarcomatoid carcinoma): report of a case.

Authors:  G De Rosa; V Donofrio; N De Rosa; F Fulciniti; P Zeppa
Journal:  Int J Gynecol Pathol       Date:  1991       Impact factor: 2.762

4.  Testing of two binary grading systems for FIGO stage III serous carcinoma of the ovary and peritoneum.

Authors:  Jeffrey D Seidman; Iren Horkayne-Szakaly; Jonathan A Cosin; Hyung S Ryu; Moutaz Haiba; Charles R Boice; Anna V Yemelyanova
Journal:  Gynecol Oncol       Date:  2006-07-07       Impact factor: 5.482

5.  Ovarian serous tumors of low malignant potential (borderline tumors): outcome-based study of 276 patients with long-term (> or =5-year) follow-up.

Authors:  Teri A Longacre; Jesse K McKenney; Henry D Tazelaar; Richard L Kempson; Michael R Hendrickson
Journal:  Am J Surg Pathol       Date:  2005-06       Impact factor: 6.394

6.  Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation.

Authors:  Gad Singer; Robert Stöhr; Leslie Cope; Reiko Dehari; Arndt Hartmann; Deng-Fan Cao; Tian-Li Wang; Robert J Kurman; Ie-Ming Shih
Journal:  Am J Surg Pathol       Date:  2005-02       Impact factor: 6.394

7.  Grading ovarian serous carcinoma using a two-tier system.

Authors:  Anais Malpica; Michael T Deavers; Karen Lu; Diane C Bodurka; Edward N Atkinson; David M Gershenson; Elvio G Silva
Journal:  Am J Surg Pathol       Date:  2004-04       Impact factor: 6.394

Review 8.  Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis.

Authors:  Ie-Ming Shih; Robert J Kurman
Journal:  Am J Pathol       Date:  2004-05       Impact factor: 4.307

9.  The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: a morphologic and molecular genetic analysis.

Authors:  Reiko Dehari; Robert J Kurman; Sanjay Logani; Ie-Ming Shih
Journal:  Am J Surg Pathol       Date:  2007-07       Impact factor: 6.394

10.  Early recurrence of ovarian serous borderline tumor as high-grade carcinoma: a report of two cases.

Authors:  Robin L Parker; Philip B Clement; David J Chercover; Thangaraja Sornarajah; C Blake Gilks
Journal:  Int J Gynecol Pathol       Date:  2004-07       Impact factor: 2.762

View more
  1 in total

Review 1.  The clinical characteristics and treatment of ovarian malignant mesoderm mixed tumor: a systematic review.

Authors:  Xin Wang; Shiyuan Wang; Shujuan Yao; Wei Shi; Ke Ma
Journal:  J Ovarian Res       Date:  2022-09-16       Impact factor: 5.506

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.